Inovatyon second-line chemotherapy ovarian cancer | Not Recruiting
Inovatyon second-line chemotherapy ovarian cancer

Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Gynaecological cancer, ovarian cancer
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN55984729
Primary Trial ID Number
Summary
Not provided at time of registration
Research Details
  • No data are available comparing trabectedin + PLD to a platinum-based regimen. Based on data from OVA-301 and CALYPSO the proposed INOVATYON trial will investigate the role of a non-platinum combination for the treatment of ovarian cancer patients relapsing between six and 12 months after last platinum-based chemotherapy 1. Does the combination of trabectedin and PLD prolong overall survival over carboplatin + PLD? 2. Progression Free Survival, response rate, safety profile, quality of life,Time from randomization to subsequent chemotherapy, response rate and progression free survival after subsequent therapies, overall survival counted from the administration of subsequent chemotherapy Sub study (Italy Only) Pharmacokinetic analyses in plasma and ascites in a subset of patients receiving trabectedin and PLD 1. To demonstrate that the combination of trabectedin (Yondelis®) and pegylated liposomal doxorubicin (PLD) prolongs overall survival (OS) over carboplatin and PLD in patients with relapsed ovarian cancer progressing within 6-12 months after end of last platinum. 2. To evaluate the time from randomization to subsequent chemotherapy and the overall survival counted from the administration of subsequent chemotherapy. 2.1. To evaluate serological response of CA-125 in each arm. 2.2. To compare the quality of life (QoL) in each arm using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (QLQ-C30) and the Quality of Life Questionnaire-OV28 (QLQ-OV28). 2.3. To compare safety profile, progression free survival (PFS), objective response rate (ORR), the type and length of remission (response rate and PFS) after subsequent therapies following each of the two combinations. 2.4. Sub-study in selected centers (ITALY ONLY): To perform pharmacokinetic (PK) analyses in both plasma and ascites in a subset of patients receiving trabectedin and PLD
Phase
Phase III
Study Design
Randomised interventional treatment
Study Type
Interventional
Intervention

Yondelis & PLD versus Carboplatin & PLD Patients are either given trabectedin (Yondelis®) and pegylated liposomal doxorubicin (PLD) or carboplatin and PLD

Intervention Type
Drug
Primary Outcome Measures
  • Demonstrate that the combination of trabectedin (Yondelis®) and pegylated liposomal doxorubicin
Secondary Outcome Measures
  • 1. CA-125 response
  • 2. To evaluate serological response of CA-125 in each arm
  • 3. Quality of life
  • 4. To compare the quality of life (QoL) in each arm using the European Organization for Research
  • 5. Safety Profile
  • 6. To compare safety profile, progression free survival (PFS), objective response rate (ORR)
  • Sub study (Italy only):
  • 1. To perform pharmacokinetic (PK) analyses in both plasma
  • 2. Time to subsequent chemotherapy
  • 3. To evaluate the time from randomization to subsequent chemotherapy and the overall survival counted
Publication(s)
Sorry, this information is not available
Result Reports
Sorry, this information is not available
Gender
Female
Age Range
Adult
Who Can Participate
Patient
Number of Participants
Planned Sample Size: 588. 442 events and about 588 patients are needed
Participant Inclusion Criteria
  • 1. Female, aged = 18 years
  • 2. Histologically and/or cytologically proven epithelial ovarian, epithelial fallopian tube cancer or primary peritoneal cancer
  • 3. Progression-free interval between six and twelve (6-12) months (calculated from the first day of the last cycle of the last platinum-based chemotherapy until the date of progression confirmation through radiologic imagery). Patients may have received up to two platinum-based chemotherapy lines, of which at least one must have contained a taxane
  • 4. Measurable or evaluable disease confirmed by radiological imaging, such as magnetic resonance imaging (MRI), computed tomography (CT) scan, or PET/CT scan at study entry. CA-125 rise not supported by radiological evidence of disease is not accepted as criteria for defining progression) or histological proven recurrent ovarian cancer even in the absence of postoperatively measurable or evaluable lesions
  • 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2
  • 6. Estimated life expectancy = 12 weeks
  • 7. Patients must be accessible for treatment and follow-up
  • 8. Adequate organ function within 14 days prior to first cycle as evidenced by:
  • 8.1. Peripheral blood counts and serum chemistry values:
  • 8.1.1. Hemoglobin ³ 9 g/dl
  • 8.1.2. Absolute neutrophil count (ANC) ³ 1,500/ml
  • 8.1.3. Platelet count ³ 100,000/ml
  • 8.1.4. Estimated glomerular filtration rate > 60 ml/min according to the Cockroft-Gault formula
  • 8.1.5. Creatine phosphokinase (CPK) = 2.5 x ULN
  • 8.2. Hepatic function variables:
  • 8.2.1. Total bilirubinULN
  • 8.2.2. Total alkaline phosphatase 2.5 ULN (consider hepatic isoenzymes 5-nucleotidase if the elevation could be osseous in origin)
  • 8.2.3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be £ 2.5 x ULN
  • 9. Patients must be able to receive dexamethasone or its equivalent, which is required if randomly assigned to treatment with trabectedin plus PLD
  • 10. Informed consent of the patient
Participant Exclusion Criteria
  • 1. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g., Mullerian tumors)
  • 2. Patients who did not respond to last platinum-based therapy or in whom last relapse occurred < 6 months or > 12 months from the last dose of platinum
  • 3. Bowel obstruction, sub-occlusive disease or the presence of symptomatic brain metastases
  • 4. Pre-existing grade > 1 motor or sensory neuropathy according to the National Cancer Institute Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 4.0
  • 5. Myocardial infarct within six months before enrolment, New YorkHeart Association (NYHA) Class II or worse heart failure, uncontrolled angina, severe uncontrolled ventricular arrythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
  • 6. History of liver disease
  • 7. Concurrent severe medical problems or any unstable medical condition unrelated to malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
  • 8. Breastfeeding women and women of child bearing potential must use effective contraception during treatment and 3 months thereafter, which may include prescription contraceptives (oral, injection, or patch), intrauterine device, double-barrier method or male partner sterilization (not applicable to patients that are surgically sterile)
  • 9. Prior exposure to trabectedin
  • 10. Prior resistance to anthracyclines or PLD defined as a progression during anthracycline-based chemotherapy or a recurrence within 6 months from its ending
  • 11. Prior severe PLD related toxicity
  • 12. Prior exposure to cumulative doses of doxorubicin >400mg/m2 or epirubicin >720mg/m2
  • 13. Treatment with any investigational product within 30 days prior to inclusion in the study
  • 14. Patients with known hypersensitivity to Trabectedin and any of its excipients or yellow fever vaccine
  • 15. Patients with concurrent serious or uncontrolled infection
  • 16. Patients in need of yellow fever vaccine while on study chemotherapy
Trial Location(s)
Guy's Hospital
London
England
SE1 9RT
Trial Contact(s)
Primary Trial Contact
Miss Sam Ballantyne
samb@oclinical.com
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
Denmark, Finland, Germany, Italy, Spain, United Kingdom
Scientific Title
Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
EudraCT Number
2010-022949-17
Funder(s)
  • Pharma Mar (Spain)
Other Study ID Numbers
10836
Sponsor(s)
Mario Negri Gynecological Oncology Group - MaNGO (Italy)
Key Dates

Recruitment Start Date

01 May 2011

Recruitment End Date

01 Dec 2013

Trial Start Date

01 May 2011

Trial End Date

01 Dec 2013

Date Assigned

31 Oct 2011

Last Updated

19 Sep 2014